BBC NEWS Americas Africa Europe Middle East South Asia Asia Pacific Arabic Spanish Russian Chinese Welsh
BBCi CATEGORIES   TV   RADIO   COMMUNICATE   WHERE I LIVE   INDEX    SEARCH 

BBC NEWS
 You are in: Business
Front Page 
World 
UK 
UK Politics 
Business 
Market Data 
Economy 
Companies 
E-Commerce 
Your Money 
Business Basics 
Sci/Tech 
Health 
Education 
Entertainment 
Talking Point 
In Depth 
AudioVideo 


Commonwealth Games 2002

BBC Sport

BBC Weather

SERVICES 
Wednesday, 9 January, 2002, 18:29 GMT
US bank turns back on Huntingdon
Animal rights demonstration outside Huntingdon research lab
Protestors close in on Huntingdon
Beleaguered UK drug-testing firm Huntingdon Life Sciences has lost one of its main backers, in a sign that investors are becoming increasingly wary of being associated with the controversial firm.

Investment bank Stephens Group, Huntingdon's biggest shareholder and one of its leading creditors, said on Wednesday that it plans to sever all ties with the company by the end of January.

All of Stephens' interests in HLS will be taken over by as yet unnamed new investors, the US-based bank said.

The move is a fresh blow to Huntingdon, which has struggled to attract investment since being targeted by campaigners protesting against its use of animals in some drug tests.

Business as usual

HLS chief operating officer Brian Cass on Wednesday stressed that Stephens' withdrawal will not affect the company's financial position or day-to-day activities.

"We look forward with confidence to the continuation of a close and positive relationship with our new bankers and investors as we continue to focus on strengthening our business," he said in a statement.

But the move by Stephens, which owns 15.5% of HLS' shares and has lent the company around 22m, is expected to discourage other major investors from coming forward.

HLS last year moved to switch its main share listing from London to New York in order to attract more US-based investors, who, the company hoped, would be immune from the attacks directed at its UK backers.

A string of UK investors walked away from HLS last year after being targeted by demonstrators.

HLS, which carries out research under contract, has previously claimed that it accounts for only a small fraction of the estimated 2.6 million animals used in drug tests in the UK every year.

 WATCH/LISTEN
 ON THIS STORY
Brian Cass, HLS managing director
"Our main laboratory base will always be in the UK"
See also:

28 Mar 01 | Business
Lab firm ditched by share brokers
22 Mar 01 | Business
Huntingdon unveils more losses
29 Jan 01 | Business
US group bails out Huntingdon
19 Jan 01 | Business
Research industry under threat
17 Apr 01 | Business
Protesters target lab firm customer
Internet links:


The BBC is not responsible for the content of external internet sites

Links to more Business stories are at the foot of the page.


E-mail this story to a friend

Links to more Business stories